Navigation Links
Shire plc - Statement re: Media Speculation
Date:7/11/2014

DUBLIN, July 11, 2014 /PRNewswire/ --


Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. 

Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon.  Shire confirms it has held a meeting with representatives of AbbVie.

This statement is being made by Shire without the prior agreement or approval of AbbVie.

A further update will be made when appropriate.  Shareholders are strongly advised to take no action in relation to AbbVie's proposal.  There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.

A copy of this announcement will be available at http://www.shire.com.  The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

Notes to editors 

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

http://www.shire.com

 

CONTACTS 

Shire 

Stephanie Fagan

+1-201-572-9581

FTI Consulting (Media Adviser to the Company) 

Andrew Lorenz (London)

+44-77-7564-1807

Ben Atwell (London)

+44-20-3727-1000

David B. Roady (New York)

+1-212-850-5600

Robert Stanislaro (New York)

+1-212-850-5600



'/>"/>
SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Launches Online Educational Resource Center for US Patients with Ulcerative Colitis
2. Hart-Scott-Rodino Waiting Period Expires for Shires Acquisition of ViroPharma
3. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
4. Shire to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
5. Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
6. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. Shire Reaches Agreement in Principle With U.S. Government
9. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
10. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
11. Shire Changes its NASDAQ Ticker Symbol to SHPG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):